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Summary.-Using a regrowth-delay assay, we investigated structure/activity rela-
tionships for the enhancement by electron-affinic agents of the anti-tumour effect of
the nitrosourea CCNU against the KHT sarcoma in C3H mice. A series of neutral
2-nitroimidazoles similar in electron affinity but varying in octanol/water partition
coefficient (PC) over 4 orders of magnitude (0.016->200, Misonidazole=0.43) were
examined at a fixed dose of 2-5 mmol/kg. A parabolic (quadratic) dependence of
activity on log PC was observed. Analogues more hydrophilic than misonidazole
(MISO) were inactive as were those with very high PCs (>20). Those with PC 0.43-
20 were usually more active than MISO, some considerably so. The fairly lipophilic
5-nitroimidazoles nimorazole and metronidazole (METRO) had similar activity to
MISO, despite their reduced electron affinity. Two basic 2-nitroimidazoles more
efficient as radiosensitizers in vitro likewise showed activity comparable to MISO.
We also investigated several agents more electron-affinic than MISO, including
some non-nitro compounds. Most were inactive at maximum tolerated doses, but
nitrofurazone showed reasonable activity. Sensitizer dose-response curves were
obtained for MISO, METRO and two of the most effective agents, benznidazole
(go 07-1051) and Ro 07-1902. The two latter agents were both considerably more
active than MISO at low doses (0-1-0.9 mmol/kg).
- These studies indicate that the structural features of electron-affinic agents res-
ponsible for the enhancement of KHT tumour response to CCNU, are quite different
from those affecting radiosensitization, lipophilicity being particularly important.
The microsomal enzyme-inhibitor SKF 525A increased the anti-tumour effect of
CCNU, suggesting inhibition of CCNU metabolism as one possible mechanism con-
tributing to chemosensitization by lipophilic electron-affinic agents in mice.
SEVERAL RECENT STUDIES have shown
that, as well as sensitizing hypoxic cells
to radiation, electron-affinic nitroimida-
zoles such as misonidazole (MISO) and
metronidazole (METRO) can enhance the
in-vivo anti-tumour activity of cytotoxic
agents (reviewed by McNally, 1982;
Brown, 1982). This effect is seen par-
ticularly with nitrogen mustards and
nitrosoureas, and in some cases there is
evidence that enhancement ofcytotoxicity
can be greater in tumours than in dose-
limiting normal tissues.
To optimize combination strategies of
this kind, structure/activity relationship
studiesareneededtoidentifythe molecular
features required by both the cytotoxic
drug and the electron-affinic sensitizer.
In a preceding paper we described the
interactions between either MISO or
METRO and a number of cytotoxics in
the RIF-1 tumour (Twentyman & Work-
man, 1982). Here we report on the
structure/activity relationships for the en-
hancement by a variety of electron-
affinic agents of the anti-tumour effects
of the nitrosourea CCNU against the
KHT sarcoma in C3H mice. CCNU was
chosen on the basis of previous studies
which showed a considerable increase inP. WORKMAN AND P. R. TWENTYMAN
KHT tumour response byMISO (Siemann,
1981, 1982; Twentyman, 1981). The elec-
tron-affinic agents included a range of
nitroheterocyclics differing widely in lipo-
philicity and electron affinity, as well as a
selection of non-nitro compounds. Some
preliminary results have been published
previously (Workman & Twentyman,
1981, 1982).
METHODS
Compounds.-MISO, desmethylmisonida-
zole (Ro 05-9963, DEMIS), benznidazole
(Ro 07-1051), BENZO, and the nitro-
imidazoles designated Ro- were supplied by
Roche (Welwyn) and those with the prefix
SR- by SRI International. METRO was
supplied by May and Baker, nimorazole
by Farmitalia Carlo Erba, NSC 38087 and
RSU 1047bytheInstituteofCancer Research,
Sutton, and CB 1954 by the Chester Beatty
Research Institute, London. Nitrofurantoin,
azathioprine, duroquinone, menadione and
imidazole were obtained from Sigma, nitro-
furazone from Koch-Light and anthraqui-
none-2-sulphonate from BDH. SKF 525A
(,3-diethylaminoethyl diphenylpropylacetate
hydrochloride, or proadifen hydrochloride)
was supplied by Smith Kline and French
(Welwyn) and CCNU (1-(2-chloroethyl)-3-
cyclohexyl-1-nitrosurea)bytheDrugSynthesis
and Chemistry Branch of the NCI and by
Lundbeck.
Basic structural formulae are shown in
Fig. 1. Other details of structure, one-
electron reduction potentials (El) and
octanol/water partition coefficients (PC) are
given in the Table.
Mice and tumours.-C3H/He mice were
obtained from OLAC and our own breeding
colony. Both sexes were used, and were
usually 12-16 weeks old and 20-30 g on
entering experiments. They were allowed
laboratory chow and water ad lib.
Procedures for handling the KHT fibro-
sarcoma are described elsewhere (Kallman
et al., 1967; Twentyman et al., 1979). Tumours
were grown i.m. in the hind limb and treated
in the size range 300-600 mg. The time taken
for individual tumours to reach 4 x the
initial group-mean volume was calculated
and the median values for each treatment
group obtained. Growth delay was calculated
with respect to the control group. Groups
contained 8-10 mice.
Drug administration.-In most experiments
test compounds were injected 30 min
before CCNU, but in some MISO was given
immediately before. ThethreeSR- compounds
were injected i.v., all others i.p. Most were
dissolved in Hanks' balanced salt solution
(pH 7-4), and injected i.p. at 0 04 ml/g body
weight. SKF 525A was given in 0-01-0O04
ml/g, Ro 31-0602 in 0-08 ml/g and METRO
in 0-04-0-16 ml/g. Imidazole was dissolved
in Hanks' and the pH corrected to 7-4
Cl(CH2)2N(NO)CONH 7
I CCNU
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N
l 2-nitrohnidazoles
R1
N
R2
NO2
IV 4-nitrolmidazoles
N
(At NO2
N2NOC
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0
CH3
0
Vil Menadione
N
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O2N N\> R2
III 5-nitroimidazoles
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V 5-nitrofurans
0
H3C CH3
0
VII Duroquinone
0
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0
IX Anthraqulnone Sulphonate
CH3(CH2)2-C-COO(CH2)2N(CH2CH3)2 HCI
X Imidazole
XI SKF 525A
FIG. 1.-Structural formulae.
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with HCI before injecting 0 04 ml/g. BENZO
Ro 07-1127, nitrofurazone, nitrofurantoin,
NSC 38087, azathioprine and anthraquinone
sulphonate were suspended in 5000 v/v
polyethylene glycol (mol. wt 400, Sigma) in
Hanks' and injected in 0 01 ml/g. Ro
31-0752, duroquinone and menadione were
dissolved in arachis oil BP (McArthy's) and
injected in 0 01 ml/g. CCNU was stored at
-70TC and prepared within minutes of use.
It was first dissolved in ethanol and then
diluted 1:10 with 05%o w/v carboxymethyl
cellulose (BDH)/Hanks', immediately before
i.p. injection in 0-01-0 02 ml/g.
Control experiments showed that none of
the drug vehicles on their own affected
tumour growth or response to CCNU.
In screening experiments the following groups
were always included: appropriate vehicle
controls; CCNU 10 mg/kg alone; CCNU
10 mg/kg+test compound; CCNU 10 mg/kg
+MISO 2-5 mmol/kg; test compound alone.
In addition, CCNU 20 mg/kg was included
in most experiments. Compounds were
tested at 2-5 mmol/kg, but, if this proved
toxic, doses close to maximum tolerated
(MTD) were used.
The use of MISO as a positive control in
each experiment allowed normalization of
data to minimize between-experiment varia-
tion. We used an Activity Index (Al) for
enhancement ofCCNU effect, defined as:
Al=
(GDX+ccNu) -(GDx alone) -(GDccNu alone)
(GDMJso+CCN,) -(GDmiso alone)
- (GDcCNU alone)
(1)
where x is the test compound, GD is growth
delay, the MISO dose is 2-5 mmol/kg and
CCNU dose 10 mg/kg. In practice, there was
no significant growth delay for MISO alone
or for most test compounds; thus these
terms were usually omitted. Using Al values,
compounds were ranked for chemosensitiza-
tion effectiveness against MISO (Al = 1).
Multiple regression analysis was carried
out using the GLIM computer program
(Version 3).
Body temperature.-At the doses used in
this study, certain test compounds reduced
mousebodytemperature. Insomeexperiments
normal body termperatures were maintained
in an incubator or with a lamp. Tempera-
tures were measured with a rectal thermister
probe and an electrical thermometer.
RESULTS
Enhancement of CCNU response by MVIISO
Fig. 2 shows typical data for the effect
of MISO on the GD response of the KHT
tumour to CCNU. The main effect is
to remove the shoulder from the dose/
response curve. The degree ofenhancement
is about the same for 2f5 as for 5 mmol/kg,
and is similar whether MISO is given 30
min or immediately before CCNU. This
is in good agreement with the GD and
cell-survival data of Siemann (1981, 1982).
Enhancement of CCNU response by other
agents
General.-On the basis of the above
experiments, a standard procedure was
adopted for screening (see Methods).
Compounds were given at 2-5 mmol/kg
(or at MTD, ifthis was less) 30 min before
10 mg/kg CCNU. Except for CB 1954 and
azathioprine, which gave barely significant
but reproducible growth delays of about
1 day, none ofthe test compounds delayed
growth when given alone.
The response to 10 and 20 mg/kg
CCNU and 10 mg/kg CCNU plus 2 5
mmol/kg MISO were generally similar
20-
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FIG. 2.-Effect ofMISO on the response ofthe
KHT tumour to CCNU. 0, CCNU alone;
O, 5 mmol/kg MISO and A, 2.5 mmol/kg
immediately before CCNU; *, 5 mmol/kg
30 min before CCNU.
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FIG. 3. Effect of partition coefficienit oIn the enhancement of KHT tumour r'espoInse to 10 mg/kg
CCNU by neutral 2-nitroimidazoles 0, and 5-nitroimidazoles-, at 2.5 mmol/kg. For identification
of analogues see Table. The line is the best fit for the quadratic relationship (see equation (3)).
Points are means of activity indices in Table.
to those seen in Fig. 2. Data from 11
independent experiments gave the follow-
ing median growth delays: 10 mg/kg
CCNU, 1P5 days; MISO + 10 mg/kg CCNU,
4 5 days; 20 mg/kg CCNU, 10 days.
The abilities of the 26 test compounds
to modify CCNU response are summarized
in the Table. The results are expressed
in terms of an Activity Index (Al; see
Methods) which has a value of 1I0 for
MISO. Compounds with Al values >1 0
were more active than MISO, those with
values < 1*0 were less active than MISO
and those with zero values were totally
inactive. Where supplies permitted, com-
pounds were usually tested at least twice
and the results weregenerallyreproducible.
A wide range of effectiveness is apparent,
and it is important to identify the struc-
tural features responsible for activity.
Neutral 2- and 5-nitroimidazoles.-Con-
sider first the activities of the 2- and 5-
nitroimidazoles which are not charged at
physiological pH. The neutral 2-nitro-
imidazoles are compounds 1-12 and the
neutral 5-nitroimidazoles compounds 15
and16(Table).ThePCvalues forthese com-
pounds vary over 4 orders of magnitude
(0 016-> 200) with MISO intermediate
(PC= 0.43). Fig. 3 shows the relationship
between Al and log PC, and the curve
is clearly bell-shaped, indicating a para-
bolic dependence. Analogues more hydro-
philic than MISO (i.e. with lower PC)
were inactive (the SR compounds 1-3),
or considerably less active than MISO
(DEMIS, 4). In contrast, those with
PC 1-20 (i.e. more lipophilic) were
usually more active, or at least as active,
as MISO. The two most active Ro 07-1902
(7), and BENZO (9) have PC of 2-5 and
8-5 respectively. In many experiments
these analogues increased the growth
delay for 10 mg/kg CCNU to greater
than that for 20 mg/k-g CCNU alone,
giving dose-modifying factors (DMF) in
excess of 2. On the other hand, compound
8 with a similar PC (3.2) was no more
active than MISO. The two most lipo-
philic analogues 11 and 12 were com-
pletely inactive.
The 2-nitroimidazoles all have electron
affinities very similar to AITSO (El,
-390 mV). The 5-nitroimidazoles metro-
nidazole (15) and nimorazole (16) are
considerably less electron-affinic, yet had
activities similar or even superior to
MISO (Table).
MIultiple regression analysis wN-as used
to analyse the data for the neutral 2- and
5-nitroimidazoles showing measurable en-
hancement at 2-5 mmol/kg (i.e. com-
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pounds 4-10, 15 and 16). The data were
fitted to a structure/activity relationship
of the form (Hansch, 1971):
log AI=b2 log PC+b3 (log PC)2 +K (2)
where b2 and b3 are constants calculated
from the regression, and the constant K
was fixed to force the data through the
MISO datum point. The mean AI was
used for each compound, with a weighting
equal to the product of Al and the square
root of the number of estimations. The
best fit (± s.e.) obtained was:
log AI= (0-472 +0*124) log PC-
(0-567 + 0*184) log PC2+0.250
n=8, R2=0.71
(3)
where n is the number of data sets
analysed in the regression, and R2 the
multiple-correlation coefficient, which
shows that 71% of the variance in the
data is explained by Equation (3).
Omitting the quadratic term, the best fit
obtainable was:
log Al = (0.228 + 04142) log PC+ 0.0825
n=8, R2=0*25
(4)
Only 25% of the variance is explained by
Equation (4), and the improvement by
including the quadratic term is highly
significant (0'01 <P <0-025, F distribu-
tion on 1, 5 d.f.).
To determine the effect of electron
affinity, the term b1 (E1) was added to
the right-hand side of Equation (2).
There was only a slight improvement in
explained variance (78%) and this was
not significant (P > 0-25, F distribution on
1, 5 d.f.). Thus, the data are best described
by the quadratic relationship given in
Equation (3).
Others.-The 2-nitroimidazoles 13 and
14 have basic substituents which are
ionized at physiological pH. Neither was
more effective than MISO (Table).
The remaining nitroheterocyclic com-
pounds, comprising the highly electron-
affinic nitrofurans nitrofurazone (19) and
nitrofurantoin (20), the 5-substituted 4-
nitroimidazolesNSC 38087(17)andazathio-
prine (18), and the dinitrophenyl-azirdine
CB 1954 (21) were toxic at 2-5 mmol/kg.
At close to MTD nitrofurazone was
reasonably active, but less than 2-5
mmol/kg MISO, whereas azathioprine
was more active than MISO. The others
had little or no activity.
Of the non-nitro electron-affinic agents.
the two highly electron-affinic quinones,
duroquinone (22) and menadione (23)
were quite toxic, with little or no activity.
The less electron-affinic anthraquinone
sulphonate (24) was non-toxic at 2-5
mmol/kgandexhibitedreasonableactivity.
Two non-electron-affinic compounds
were investigated. Imidazole (25) was
ineffective at 2-5 mmol/kg and also at
5 mmol/kg (not shown). The hepatic
microsomal-enzyme inhibitor SKF 525A
(26) was active at 0-13 mmol/kg.
Dose/response curves.-The effect of the
dose of the electron-affinic agent on the
response of the KHT tumour to 10 mg/kg
CCNU was determined for MISO (5),
METRO (15) and the two most effective
agents Ro 07-1902 (7), and BENZO (9).
Fig. 4 shows combined data from a series
of independent experiments. In these
studies METRO was rather less active
than MISO, whereas the others were
confirmed as more active, even at low
doses. Although Ro 07-1902 (7) was the
most active at high doses, BENZO (9)
showed good activity at doses down to
0-05-0-1 mmol/kg.The dose/response curve
for BENZO is rather flat from 0'1 to
4 mmol/kg.
Fffect ofbody temperature on response
High doses of MISO, METRO and
other lipophilic nitroimidazoles cause mice
to become torpid and hypothermic (Work-
man & Brown, 1981). At 2-5 mmol/kg,
MISO decreased body temperature by
only 1-2°C and the hydrophilic analogues
had no effect. Those more lipophilic
than MISO produced a bigger decrease
(up to 5-6°C) as did anthraquinone
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FIG. 4.-Dose/response curves for the enhancement of the response of the KHT tumour to 10 mg/kg
CCNU by various nitroimidazoles. The responses to 10 and 20 mg/kg CCNU without the addition
ofnitroimidazoles are also shown ( , *). The data were obtained in two independent experiments,
indicated by the open and closed symbols.
sulphonate (24). Ro 31-0602 (10) at
2*5 mmol/kg appeared to cause temporary
paralysis, but this was not seen at lower
doses.
It seems unlikely that these effects
make a major contribution to tumour
response. Very high doses of METRO
(e.g. 10 mmol/kg) reduced temperature
by 10°C but the tumour response was
about the same as with 2-5 mmol/kg
MISO (Fig. 4). Furthermore, by reducing
the dose of the lipophilic analogues, good
tumour responses were maintained (Fig. 4)
without a marked temperature fall. In
three experiments with the active lipo-
philic analogue Ro 07-1902 (7) tumour
response to 10 mg/kg CCNU plus 2 5
mmol/kg Ro 07-1902 was determined in
mice whose body temperatures either were
allowed to fall to about 32°C or were
maintained at 36-37°C in an incubator
or with a lamp. There was no difference in
tumour response.
DISCUSSION
These studies, along with several others
(Siemann, 1981, 1982; Twentyman, 1981;
Hirst et al., 1982) demonstrate that the
response of the KHT tumour to CCNU
can be increased considerably by MISO.
Enhancement of in vivo tumour response
to CCNU by 2-5-5 mmol/kg MISO has
been demonstrated also with the RIF-1
sarcoma (Siemann, 1981, 1982; Twenty-
man, 1981; Twentyman & Workman,
1982), Lewis lung carcinoma (Stephens
et al., 1981), MT-1 mammary tumour
(Siemann, 1982), SCC VII/St carcinoma
and EMT6/St/lu tumour (Hirst et al.,
1982).We arenotawareofanyexperiments
where these doses of MISO have failed to
enhance response to CCNU. In addition,
doses of 2-5-5 mmol/kg MISO enhanced
tumour response to methyl-CCNU and
BCNTUinmosttumoursevaluated(Clement
et al., 1980; Stephens etal., 1981; Tannock,
1980b; Mulcahy et al., 1981; Clutterbuck
et al., 1982), and MISO also enhanced
KHT tumour response to PCNU but not
to chlorozotocin (Mulcahy, 1982). Taken
overall, chemosensitization with CCNU
appears to be at least as good as that seen
for other cytotoxics.
To find the best sensitizer-nitrosourea
combinations, detailed structure/activity
studies are required. The present paper
gives data for 26 compounds, mostly
electron-affinic, in combinationwithCCNU
against the KHT tumour. By analogy
with structure/activity relationships for
radiosensitization (e.g. Adams et al., 1979;
Anderson et al., 1981) wewereparticularly
I a I Ol --
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interested in the effects of lipophilicity
and electron-affinity.
Forthe neutral 2- and 5-nitroimidazoles,
PC varied from 0-014-> 200. Of those
more hydrophilic than MISO the 3 SR
compounds (1-3) were completely inactive
at 2-5 mmol/kg, and DEMIS (4) con-
siderably less effective. Siemann (1982)
observed similar results with SR-2508
(3), SR-2555 (2) and DEMIS at 5 mmol/kg.
Some enhancement of RIF-1 tumour
response was obtained with SR-2508,
but only at high CCNU doses (> 20 mg/kg)
and less than obtained with MISO. A
similar lack of effect of SR-2508 was also
seen by Hirst et al. (1982).
We observed much greater activity
with lipophilic nitroimidazoles. At 2-5
mmol/kg, several MISO analogues with
PC 1-10 gave superior enhancement of
CCNU response (Fig. 3). Furthermore,
Ro 07-1902 (7) and particularly BENZO
(9) were active at much lower doses than
MISO (Fig. 4). The superior activity of
BENZO has been confirmed recently by
Siemann (personal communication). Lipo-
philicity cannot beincreased muchfurther,
however, before activity is lost, the overall
dependence being parabolic (Fig. 3).
It was not possible to examine the
influence of electron affinity on enhance-
ment of CCNU response in quite as much
depth, because of the toxicity of the
highly electron-affinic compounds. Never-
theless, enhancement data were obtained
for compounds with El values from
- 486 to - 203 mV, and are sufficient to
demonstrate that electron affinity is less
important than lipophilicity. For the
neutral 2- and 5-nitroimidazoles, multiple
regression analysis revealed no significant
advantage in including an electron-affinity
term into the quadratic expression for
lipophilicity. Of the compounds more
electron-affinic than MISO, only nitro-
furazone (19) showed comparable en-
hancement of CCNU response at MTD
(Table). The other 5-nitrofuran, nitro-
furantoin (20), was virtually inactive,
as were the non-nitro compounds duro-
quinone (22) and menadione (23). The
two quinones are very lipophilic, which
may contribute to their lack of enhance-
ment; however, the nitrofurans have PC
values close to the optimal range for
nitroimidazoles. Another non-nitro com-
pound anthraquinone-2-sulphonate (24)
has similar electron affinity to MISO,
was less toxic than the more electron-
affinic quinones, and showed reasonable
enhancement at 2-5 mmol/kg, despite
its hydrophilicity.
It is useful to compare our structure/
activity relationships for enhancement
of CCNU response in vivo with those for
radiosensitization. In vitro radiosensitiza-
tion of hypoxic cells by neutral MISO
analogues is largely dependent on electron
affinity. Although some effect is seen at
extreme PC values (Anderson et al., 1981;
Brown et al., 1982) lipophilicity has
relatively little influence. In vivo structure/
activity relationships are inevitably more
complex, because ofpharmacokinetic con-
siderations, and this applies to both
radiosensitization and chemosensitization.
However, selected examples will demon-
strate that the structural features required
for the two effects are rather different.
For example, Rauth et al. (1978) evaluated
the 2-nitroimidazoles 4, 5, 6, 7 and 11
for in vivo radiosensitization, using the
same tumour and mouse strain and similar
timing to the present study. Ro 07-1902
(7) showed radiosensitization comparable
to MISO, whereas it is considerably more
active in enhancing the CCNU response.
Both the hydrophilic DEMIS (4) and the
lipophilic Ro 07-1127 (11) gave good
radiosensitization, but have little or no
ability to enhance the CCNU response.
Pharmacokinetic considerations are clearly
not responsible for the inactivity of the
hydrophilic analogues DEMIS, SR-2508
and SR-2555 with CCNU, since these
achieve plasma andtumourlevels sufficient
for radiosensitization comparable to MISO
(Brown & Workman, 1980; Brown et al.,
1981). They may, however, contribute
to the inactivity of the most lipophilic
and the most electron-affinic analogues.
Quantitative differences in the pharma-
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cokinetics of MISO between experimental
animals and man are well established
(Workman & Brown, 1981) and therefore
caution should be exercised in extra-
polating chemosensitization data directly
to man. Pharmacokinetic studies are in
progress with this series and some pre-
liminary data have been reported (White
et al., 1982). It should be noted that the
abilityofthe markedlyhydrophilic anthra-
quinone-2-sulphonate (24) to enhance
CCNU response may be due to free
anthraquinone, since sulphonate groups
are rapidly metabolized in mice (Zanelli
& Kaelin, 1981).
Recent in vitro studies have identified
nitroimidazoles which radiosensitize hy-
poxic mammalian cells more efficiently
than predictedfrom theirelectron affinities
These include 2-nitroimidazoles with basic
alkanolamine substituents partially proto-
nated at physiological pH, and 5-sub-
stituted 4-nitroimidazoles (Adams et al.,
1980a; Smithen et al., 1980). We tested
two alkanolamines, Ro 03-8799 (13) and
RSU 1047 (14). At 2-5 mmol/kg both
enhanced CCNU activity slightly less
than MISO (Table). Two 5-substituted
4-nitroimidazoles were examined, NSC
38087 (17) and azathioprine (18). The
former was highly toxic and had little
activity at MTD. In contrast, azathioprine
at 1-4 mmol/kg was superior to 2-5
mmol/kg MISO (Table). The dinitro-
phenylaziridine CB 1954 (21) is also a
better-than-predicted radiosensitizer of
hypoxic mammalian cells (Stratford et al.,
1981, but was rather toxic and gave no
enhancement of CCNU response at MTD
(Table).
The mechanism of enhancement of
nitrosourea response is unknown, but the
main possibilities have been discussed
(Siemann, 1981, 1982; Mulcahy et al.,
1981; Brown, 1982). Enhancement of
CCNU response was seen with EMT6
tumour spheroids after prolonged hypoxic
pre-exposure to MISO invitro, and was not
due to inhibition of recovery from poten-
tially lethal damage (Twentyman, 1982).
In contrast, inhibition of clonogenic cell
recovery was seen with the KHT tumour
in vitro and carbamoylation of repair
enzymes may be involved (Mulcahy, 1982).
Depletion of glutathione by MISO has
been demonstrated (Brown, 1982). Tan-
nock (1980) showed that serum from mice
receiving MISO and BCNU (but not
BCNU alone) was preferentially cytotoxic
to hypoxic cells. Our studies show that
enhancement of CCNU response is not
due to reduced body temperature, and
this has been confirmed by Siemann
(personal communication).
Structure/activity relationships present
another approach to the mechanism.
The present studies show that the struc-
tural features responsible for the enhance-
ment of the KHT tumour response are
different from those affecting radio-
sensitization; lipophilicity being more
important and electron affinity less so.
Despite having a PC slightly greater than
MISO, imidazole (25) was inactive. This
may indicate a requirement for some
electron affinity, though not necessarily in
a nitro group, since anthraquinone sul-
phonate (24) was also effective. On the
other hand we demonstrated that, despite
having no electron affinity, SKF 525A
(26) gave good enhancement of CCNU
response, a result confirmed recently by
Siemann (personal communication). SKF
525A also increased the response of the
ascites L1210 leukaemia to methyl-CCNU
in mice, as well as reducing the LD50
(Klubes et al., 1979). A possible mechanism
which might be shared by SKF 525A and
the nitroimidazoles of intermediate lipo-
philicity would be one operating through
inhibition of re-routing of nitrosourea
metabolism. This could accommodate (1)
the absence of enhancement of CCNU
response by hydrophilic analogues which
are not metabolized, but cleared by the
kidney (Workman & Brown, 1981) and
thus are unlikely enzyme inhibitors, (2)
the lack ofenhancement ofresponse to the
hydrophilic nitrosourea chlorozotocin,
also cleared by the kidney (Hoth et al.,
1978) and (3) the lack of enhancement of
CCNU response by the highly electron-
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affinicand othertoxicanalogues, becauseof
inadequate concentrations for inhibition.
The principal aim of this investigation
was to identify for further attention
compounds which might be superior
chemosensitizers to MISO. The lipophilic
analogues, particularly Ro 07-1902 and
BENZO, clearly warrant more detailed
evaluation.BENZOisofparticular interest
becausethetumourenhancementsreported
here occur with doses much lower than
with MISO, and plasma and tumour
concentrations corresponding to active
doses in mice can be maintained for
several hours in dogs (White et al., 1982).
Daily doses ofup to 0 03 mmol/kg BENZO
have been used in the treatment of
Chaga's disease in man (Coura et al.,
1978) and the drug is eliminated with a
half-life similar to MISO (Raaflub, 1980).
Preliminary studies in mice have demon-
strated a therapeutic gain for combining
BENZO with CCNU, and BENZO is now
undergoing preliminary clinical evaluation
as a chemosensitizer in this Unit.
In view of the therapeutic advantage
which has been reported for the combina-
tion of MISO with CCNU (Siemann,
1981, 1982; Twentyman & Workman,
1982a; Hirst et al., 1982) we are now
evaluating the effect ofcombining BENZO
or Ro 07-1902 with CCNU, and also with
other cytotoxics for which they show
improved enhancement over MISO, i.e.
chlorambucil and cyclophosphamide
(Twentyman & Workman, 1982b) and
Melphalan (Sheldon & Batten, 1982;
Clutterbuck & Miller, personal communi-
cation). We are also optimizing the dose
schedules, with emphasis on relevance to
clinical pharmacokinetics.
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Note added in proof: We have recently
examined sensitization of the KHT tum-
our to CCNU by 1-(2-hydroxy-3-meth-
oxypropyl) - 2 - methyl - 4 - nitroimidazole
(Watras et al., 1979, Br. J. Cancer, 40,
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